Why it matters
Names trading close to their 52-week low. It is best used as a valuation shortlist, not a buy list: the strongest candidates still need balance-sheet, cash-flow and competitive-position checks.
Names trading close to their 52-week low.
Stocks near their 52-week lows are where contrarians hunt for mispricing — some are value, some are value traps. This collection screens for names trading within roughly 15% of their yearly low; pair it with the Reward and Risk ratings to tell them apart.
Names trading close to their 52-week low. It is best used as a valuation shortlist, not a buy list: the strongest candidates still need balance-sheet, cash-flow and competitive-position checks.
Look for durable margins, sensible debt, cash conversion and whether the market is pricing in a temporary problem or a permanent decline.
Cheap or high-quality screens can still contain value traps when earnings are peaking, accounting quality is poor or the business model is losing relevance.
Showing the 40 largest of 1476 — sort or filter to explore the rest.
Names trading close to their 52-week low. It currently holds 1476 stocks, each rated by Openbook's Reward and Risk scores. Stocks near their 52-week lows are where contrarians hunt for mispricing — some are value, some are value traps.
Constituents are chosen by a rules-based screen over the full UK and US common-stock universe, then ranked by market capitalisation.
It is rebuilt from live market data, so the constituents and their rankings update as prices and company fundamentals change — there is no fixed, hand-edited list.
Openbook's Reward rating combines a stock's growth, momentum, profitability and valuation into a single 0–100 score, and the Risk rating scores financial strength, volatility and size. Use them to compare names within this theme — broadly, a higher Reward alongside a lower Risk is more attractive. They are quantitative research signals, not investment advice.
Openbook Reward and Risk ratings and factor scores are quantitative signals for research, not investment advice. Data may be delayed. Some US-listed names carry partial factor coverage.